Novartis to Acquire Korro Bio for Up to $855M

TL;DR

Novartis is buying Korro Bio for up to $855M to get its RNA tech.

AI Summary

Korro Bio, Inc. announced on April 22, 2024, that it has entered into a definitive agreement to be acquired by Novartis AG. The transaction is valued at up to $855 million, including an upfront payment and potential milestone payments. This acquisition aims to leverage Korro Bio's novel RNA-based therapeutics platform.

Why It Matters

This acquisition by a major pharmaceutical company like Novartis signifies strong validation for Korro Bio's RNA-based drug discovery technology and could accelerate the development of new treatments.

Risk Assessment

Risk Level: medium — The deal is subject to customary closing conditions, including regulatory approvals, and the ultimate value depends on achieving future milestones.

Key Numbers

• $855M — Acquisition Value (Maximum potential value of the transaction between Korro Bio and Novartis.)

Key Players & Entities

• Korro Bio, Inc. (company) — Registrant
• Novartis AG (company) — Acquiring company
• $855 million (dollar_amount) — Maximum acquisition value
• April 22, 2024 (date) — Date of report and announcement

FAQ

Key Financial Figures

• $0.001 — ich registered Common stock, par value $0.001 per share KRRO The Nasdaq Capital M
• $70.0 m — gregate purchase price of approximately $70.0 million, or $56.00 per share. The private
• $56.00 — rice of approximately $70.0 million, or $56.00 per share. The private placement was le
• $166.4 million — th our existing cash and equivalents of $166.4 million as of December 31, 2023, will provide r

Filing Documents

• d814636d8k.htm (8-K) — 28KB
• 0001193125-24-105037.txt ( ) — 157KB
• krro-20240422.xsd (EX-101.SCH) — 3KB
• krro-20240422_lab.xml (EX-101.LAB) — 19KB
• krro-20240422_pre.xml (EX-101.PRE) — 12KB
• d814636d8k_htm.xml (XML) — 4KB

Forward-Looking Statements

Forward-Looking Statements Certain statements in this current report on Form 8-K may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statement include, but are not limited to, express or implied statements regarding our expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, express or implied statements regarding the intended use of proceeds. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "strive," "would," "aim," "target," "commit," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking. Forward-looking statements are based on current expectations and assumptions that, while considered reasonable are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including risks inherent in biopharmaceutical development generally, such as risks associated with pre-clinical studies and clinical trials and other risks associated with obtaining regulatory approvals and protecting intellectual property; as well as other risks and uncertainties indicated from time to time in our filings with the SEC, including Item 1A. "Risk Factors" in our Annual Report on Form 10-K filed with the SEC on the March 26, 2024, as such may be amended or supplemented by our other filings with the SEC. No

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KORRO BIO, INC. Date: April 22, 2024 By: /s/ Ram Aiyar Name: Ram Aiyar Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR